Quarterly report pursuant to Section 13 or 15(d)

Collaborative Arrangements - GSK Platform Technology Transfer, Collaboration and License Agreement (Details)

v3.20.2
Collaborative Arrangements - GSK Platform Technology Transfer, Collaboration and License Agreement (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Jul. 31, 2014
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue recognized $ 18,385,000 $ 21,906,000 $ 48,023,000 $ 49,808,000    
GSK [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue recognized         $ 2,000,000.0  
GSK [Member] | Research and Development Revenue [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue recognized $ 0 $ 2,000,000.0 $ 0 $ 2,000,000.0    
GSK [Member] | Minimum [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Contingent receivable           $ 5,750,000
GSK [Member] | Maximum [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Contingent receivable           $ 38,500,000